[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571791":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":24,"locations":30,"responsibleParty":129,"collaborators":10,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":10,"eligibilityCriteria":137,"healthyVolunteers":133,"sex":138,"minAge":139,"maxAge":10,"enrollmentInfo":140,"targetDuration":10,"studyType":143,"phases":10,"briefSummary":144,"conditions":145,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"Cohort A",null,"Healthy controls from asthma translational study: approximately 50 healthy participants aged 30 or older.",{"label":13,"type":10,"description":14,"interventionNames":10},"Cohort B","pre-COPD or PRISm: approximately 110 participants at 30 to 50 years of age (inclusive) with respiratory symptoms and\u002For structural lung lesions and\u002For physiological abnormalities without airflow obstruction (FEV1\u002FFVC \\>= 0.7 post-bronchodilation). PRISm is defined as preserved ratio (FEV1\u002FFVC \\>= 0.7 post-bronchodilation) with impaired spirometry (FEV1 \\\u003C 80% of reference post-bronchodilation).",{"label":16,"type":10,"description":17,"interventionNames":10},"Cohort C1","Mild COPD (Cohort C): approximately 110 physician-diagnosed COPD participants in total with post-bronchodilation FEV1\u002FFVC \\\u003C 70% and FEV1 \\>= 80% of predicted. Cohort C1: participants at 30 to 50 years of age (inclusive).",{"label":19,"type":10,"description":20,"interventionNames":10},"Cohort C2","Mild COPD (Cohort C): approximately 110 physician-diagnosed COPD participants in total with post-bronchodilation FEV1\u002FFVC \\\u003C 70% and FEV1 \\>= 80% of predicted. Cohort C2: participants elder than 50 years of age (exclusive) within Cohort C mild COPD (approximately 110 total across C1 and C2).",{"label":22,"type":10,"description":23,"interventionNames":10},"Corhort D","Moderate to very severe COPD: approximately 330 COPD participants (males and females aged 50 years or older) with moderate to very severe airflow limitation defined as post-bronchodilation FEV1\u002FFVC \\\u003C 70% and FEV1 \\>= 25% and \\\u003C 80% of predicted, and presence of respiratory symptoms equivalent to CAT \\>= 10 or mMRC \\>= 2.",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[31,43,50,57,64,71,78,85,92,97,104,108,115,122],{"facility":32,"status":33,"city":34,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Research Site","RECRUITING","Beijing","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},{"facility":32,"status":33,"city":44,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":45,"geoPoint":49,"contacts":10},"Changsha",{"type":38,"coordinates":46},[47,48],112.97087,28.19874,{"lat":48,"lon":47},{"facility":32,"status":33,"city":51,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Chengdu",{"type":38,"coordinates":53},[54,55],104.06667,30.66667,{"lat":55,"lon":54},{"facility":32,"status":33,"city":58,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":59,"geoPoint":63,"contacts":10},"Guangzhou",{"type":38,"coordinates":60},[61,62],113.25,23.11667,{"lat":62,"lon":61},{"facility":32,"status":33,"city":65,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":66,"geoPoint":70,"contacts":10},"Hefei",{"type":38,"coordinates":67},[68,69],117.28083,31.86389,{"lat":69,"lon":68},{"facility":32,"status":33,"city":72,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Nanjing",{"type":38,"coordinates":74},[75,76],118.77778,32.06167,{"lat":76,"lon":75},{"facility":32,"status":33,"city":79,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":80,"geoPoint":84,"contacts":10},"Nanning",{"type":38,"coordinates":81},[82,83],108.31667,22.81667,{"lat":83,"lon":82},{"facility":32,"status":33,"city":86,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":87,"geoPoint":91,"contacts":10},"Shanghai",{"type":38,"coordinates":88},[89,90],121.45806,31.22222,{"lat":90,"lon":89},{"facility":32,"status":93,"city":86,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":94,"geoPoint":96,"contacts":10},"NOT_YET_RECRUITING",{"type":38,"coordinates":95},[89,90],{"lat":90,"lon":89},{"facility":32,"status":93,"city":98,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":99,"geoPoint":103,"contacts":10},"Shenyang",{"type":38,"coordinates":100},[101,102],123.43278,41.79222,{"lat":102,"lon":101},{"facility":32,"status":33,"city":98,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":105,"geoPoint":107,"contacts":10},{"type":38,"coordinates":106},[101,102],{"lat":102,"lon":101},{"facility":32,"status":33,"city":109,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":110,"geoPoint":114,"contacts":10},"Wuhan",{"type":38,"coordinates":111},[112,113],114.26667,30.58333,{"lat":113,"lon":112},{"facility":32,"status":33,"city":116,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":117,"geoPoint":121,"contacts":10},"Xuzhou",{"type":38,"coordinates":118},[119,120],117.28386,34.20442,{"lat":120,"lon":119},{"facility":32,"status":33,"city":123,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":124,"geoPoint":128,"contacts":10},"Zhengzhou",{"type":38,"coordinates":125},[126,127],113.64861,34.75778,{"lat":127,"lon":126},{"type":130,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100571791","a-translational-study-for-prediction-of-biomarkers-and-identification-of-phenotype-and-endotype-of-copd-and-pre-copd-outcomes-in-chinese-population-100571791",false,"NCT06724848","A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population","A Translational Study in Patients With COPD and Pre-COPD to Describe Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population","Inclusion Criteria:\n\n* Capable of giving signed ICF\n* Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society and European Respiratory Society 2019 acceptability criteria.\n* Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center.\n* Participants will be allowed to enroll into other non-intervention studies while taking part in this study.\n\nExclusion Criteria:\n\n* The participant has a history of alcohol or drug abuse within the past year, which, in the opinion of the responsible physician, contra-indicates their participation.\n* The participant has an altered mental status at the time of informed consent.\n* Clinically significant abnormal laboratory values available vital signs, ECG, or laboratory testing at the screening assessment that, which in the opinion of the investigator, could interfere with the objectives of the study or safety of the participant. -Current diagnosis of asthma.\n* Clinically important pulmonary disease.\n* COPD exacerbation, within 2 weeks prior to enrollment or during screening period.\n* History of partial or total lung resection (single lobe or segmentectomy is acceptable). Surgical or endoscopic (eg, valves) lung volume reduction within the 6 months prior to enrollment. Expected need for lung volume reduction surgery during the study.\n* Unstable disorders.\n* Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrollment. Suspected malignancy or undefined neoplasms.\n* Terminal disease and\u002For organ failure or participants otherwise considered not appropriate for the study participation.\n* Participants receipt marketed or investigational biologics biologics within 3 months or 5 half-lives prior to visit 1, whichever is longer.\n* Female participants who are pregnant.","ALL","30 Years",{"count":141,"type":142},850,"ESTIMATED","OBSERVATIONAL","This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory\u002Fimmunological mechanisms on pre-COPD or PRISm, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants for 1-year period.",[146],"COPD","2026-06-01",{"date":149,"type":150},"2026-06-02","ACTUAL",{"date":152,"type":150},"2024-06-05",{"date":154,"type":142},"2027-10-21",{"name":5,"class":6},14]